Anna Sureda
Institut Català d'Oncologia, Hospital Duran i Reynals · Hospital Sant Pau Barcelona · Hospital de la Santa Cruz i Sant Pau
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Anna Sureda as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:59 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04378647 · BREntuximab Vedotin in SEcond LIne Therapy BEfore TransplantGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea · unknown · Hodgkin Lymphoma, Adult · principal investigator
- Ph3NCT00560053 · Pethema Multiple Myeloma 2000PETHEMA Foundation · completed · Multiple Myeloma · study chair
- Ph3NCT00017277 · Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Head and Neck CancerEuropean Organisation for Research and Treatment of Cancer - EORTC · terminated · Head and Neck Cancer · study chair
- Ph3NCT00049595 · Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's LymphomaEuropean Organisation for Research and Treatment of Cancer - EORTC · completed · Lymphoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:59 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:59 UTC. The ranking covers the 200 most relevant of 125 PubMed records, and a shared surname and initials can bring in a namesake. All 125 on PubMed
- Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.N Engl J Med · 20221,394 citationsRCR 94.5
- Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.N Engl J Med · 2022695 citationsRCR 47.5
- 575 citationsRCR 17.9
- Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.N Engl J Med · 2022459 citationsRCR 30.2
- Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.N Engl J Med · 2023428 citationsRCR 35.5
- 398 citationsRCR 20.0
- 377 citationsRCR 8.7
- 377 citationsRCR 9.5
- 294 citationsRCR 6.7
- Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.N Engl J Med · 2022257 citationsRCR 20.2